ArticleCancer communications (London, England)2020

A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.

Xiao-Li Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.